

## **Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities LLC**

Leuven, BELGIË – 9 december 2024 – 18u00 CET [Oxurion NV](#) (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving<sup>1</sup>, de volgende transparantiekennisgevingen heeft ontvangen:

Oxurion ontving een transparantiekennisgeving op 6 december 2024 van Atlas Special Opportunities LLC waaruit blijkt dat het op 5 december 2024 564.856 aandelen van de toen uitstaande 2.567.406 aandelen bezat en dus boven de drempel (20%) kwam door de aankoop van stemrechtverlenende effecten.

Oxurion ontving een transparantiekennisgeving op 6 december 2024 van Atlas Special Opportunities LLC waaruit blijkt dat het op 6 december 2024 496.161 aandelen van de toen uitstaande 2.567.406 aandelen bezat en dus onder de drempel (20%) kwam door de verkoop van stemrechtverlenende effecten.

### **Over Oxurion**

Oxurion (Euronext Brussel: OXUR) houdt zich bezig met de ontwikkeling van de volgende generatie standaard oftalmologische therapieën voor de behandeling van netvliesafwijkingen. Oxurion is gevestigd in Leuven, België. Meer informatie is beschikbaar op [www.oxurion.com](http://www.oxurion.com).

### ***Belangrijke informatie over toekomstgerichte verklaringen***

Bepaalde verklaringen in dit persbericht kunnen als "toekomstgericht" worden beschouwd. Dergelijke toekomstgerichte verklaringen zijn gebaseerd op de huidige verwachtingen en brengen dienovereenkomstig verschillende risico's en onzekerheden met zich mee en worden ze beïnvloed. Het bedrijf kan daarom geen enkele garantie geven dat dergelijke toekomstgerichte verklaringen zullen materialiseren en aanvaardt geen enkele verplichting om een toekomstgerichte verklaring bij te werken of te herzien, hetzij als gevolg van nieuwe informatie, toekomstige gebeurtenissen of enige andere reden. Aanvullende informatie over risico's en onzekerheden die van invloed zijn op het bedrijf en andere factoren die ertoe kunnen leiden dat de werkelijke resultaten wezenlijk verschillen van een toekomstgerichte verklaring, is opgenomen in het jaarverslag van het bedrijf. Dit persbericht vormt geen aanbod of uitnodiging voor de verkoop of aankoop van effecten of activa van Oxurion in enig rechtsgebied. Er mogen geen effecten van Oxurion worden aangeboden of verkocht in de Verenigde Staten zonder registratie onder de U.S. Securities Act van 1933, zoals gewijzigd, of in overeenstemming met een vrijstelling daarvan, en in overeenstemming met toepasselijke Amerikaanse effectenwetten.

### **Voor meer informatie kunt u contact opnemen met:**

|  |
|--|
| <p><a href="#">Oxurion NV</a><br/>Pascal Ghoson<br/>Chief Executive Officer<br/><a href="mailto:Pascal.ghoson@oxurion.com">Pascal.ghoson@oxurion.com</a></p> |
|--|

1. Art 14, eerste alinea, van de Wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen.

# ANNEX 1

### 1) Status of the notification

Final

### 2) Issuer

Name: OXURION  
 Identification number: 0881-620-924

### 3) Reason for the notification

Acquisition or disposal of voting securities or voting rights

### 4) Notification by

A person that notifies alone

### 5) Persons subject to the notification requirement

| Name                            | Address (for legal entities)                           |
|---------------------------------|--|
| Atlas Special Opportunities LLC | 2500 Westchester Avenue, Suite 401, Purchase, NY 10577 |

### 6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

| Name | Address (for legal entities) |
|------|------------------------------|
|      |                              |

**i** Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6

Part II

### 7) Date on which the threshold is crossed

05/12/2024 (DD/MM/YYYY)

### 8) Threshold that is crossed (in %)

20

**i** If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

### 9) Denominator

2,567,406


**i** Please enter the denominator before filling in the data

### 10) Notified details

| A) Voting rights                | Previous notification | After the transaction |                              |                      |                              |
|---------------------------------|-----------------------|-----------------------|------------------------------|----------------------|------------------------------|
|                                 | # of voting rights    | # of voting rights    |                              | % of voting rights   |                              |
| Holders of voting rights        |                       | Linked to securities  | Not linked to the securities | Linked to securities | Not linked to the securities |
| Atlas Special Opportunities LLC | 97,098                | 564,856               | 0                            | 22.00%               | 0.00%                        |
| <b>TOTAL</b>                    |                       | <b>564,856</b>        | <b>0</b>                     | <b>22.00%</b>        | <b>0.00%</b>                 |

**i** Start with "groups" of holders. Add subtotals with  $\Sigma$ , and then finish with the persons who are "alone". For groups, start with the ultimate controlling natural person or legal entity. The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

| B) Equivalent financial instruments         |                              | After the transaction |                         |  |                    |            |
|---|------------------------------|-----------------------|-------------------------|--|--------------------|------------|
| Holders of equivalent financial instruments | Type of financial instrument | Expiration date       | Exercise period or date | # of voting rights that may be acquired if the instrument is exercised | % of voting rights | Settlement |
|   |                              |                       |                         |  |                    |            |
| TOTAL                                       |                              |                       |                         | 0  | 0.00%              |            |

 The totals will be updated once you have clicked on <CALCULATE>

| TOTAL (A & B) | # of voting rights | % of voting rights |
|---------------|--------------------|--------------------|
|               | 564,856            | 22.00%             |

CALCULATE

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder  will cease to hold / will hold again  voting rights as of  (DD/MM/YYYY)


13) Additional information

On 2 December 2024 (with settlement date on 4 December 2024), Atlas Special Opportunities LLC sold 97,098 shares in Oxurion NV, as a result of which its shareholding decreased to 0 shares (= 0.00%, denominator = 2,567,406).  
 On 3 December 2024 (with settlement date on 5 December 2024), Atlas Special Opportunities LLC acquired 564,856 shares in Oxurion NV, as a result of which its shareholding increased to 564,856 shares (= 22.00%, denominator = 2,567,406).

Done at  New York

On  05/12/2024 (DD/MM/YYYY)

Name & capacity  Patrick Vance, Proxyholder

Signature  

For security reasons, the unsigned form in **xlsx** format should be transmitted to [trp.fin@fsmn.be](mailto:trp.fin@fsmn.be). You can do this manually OR if you have MS Outlook at your disposal via the "Save & Send" button.

In addition, a signed copy in **PDF** format should also be transmitted.

**ANNEX 2**

1) Status of the notification

Final

2) Issuer

Name: OXURION  
Identification number: 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights

4) Notification by

A person that notifies alone

5) Persons subject to the notification requirement

| Name                            | Address (for legal entities)                           |
|---------------------------------|--|
| Atlas Special Opportunities LLC | 2500 Westchester Avenue, Suite 401, Purchase, NY 10577 |

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

| Name | Address (for legal entities) |
|------|------------------------------|
|      |                              |

Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6

Part II

7) Date on which the threshold is crossed

06/12/2024 (DDMMYYYY)

8) Threshold that is crossed (in %)

20

If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

2,567,406


Please enter the denominator before filling in the data

10) Notified details

| A) Voting rights                | Previous notification<br># of voting rights | After the transaction |                              |                      |                              |
|---------------------------------|---|-----------------------|------------------------------|----------------------|------------------------------|
|                                 |   | # of voting rights    |                              | % of voting rights   |                              |
| Holders of voting rights        |   | Linked to securities  | Not linked to the securities | Linked to securities | Not linked to the securities |
| Atlas Special Opportunities LLC | 564,856                                     | 496,161               |                              | 19.33%               |                              |
| <b>TOTAL</b>                    |   | <b>496,161</b>        | <b>0</b>                     | <b>19.33%</b>        | <b>0.00%</b>                 |

Start with "groups" of holders. Add subtotals with  $\Sigma$ , and then finish with the persons who are "alone". For groups, start with the ultimate controlling natural person or legal entity. The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

| B) Equivalent financial instruments         | After the transaction        |                 |                         |  |                    |            |
|---|------------------------------|-----------------|-------------------------|--|--------------------|------------|
| Holders of equivalent financial instruments | Type of financial instrument | Expiration date | Exercise period or date | # of voting rights that may be acquired if the instrument is exercised | % of voting rights | Settlement |
|   |                              |                 |                         |  |                    |            |
| TOTAL                                       |                              |                 |                         | 0  | 0.00%              |            |

 The totals will be updated once you have clicked on <CALCULATE>

|               |                  |                    |                    |
|---------------|------------------|--------------------|--------------------|
| TOTAL (A & B) |                  | # of voting rights | % of voting rights |
|               | <b>CALCULATE</b> | 496,161            | 19.33%             |

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder  will cease to hold / will hold again  voting rights as of  (DD/MM/YYYY)


13) Additional information

On 4 December 2024 (with settlement date on 6 December 2024), Atlas Special Opportunities LLC sold 68,695 shares in Oxurion NV, as a result of which its shareholding decreased to 496,161 shares (= 19.33%, denominator = 2,567,406).

Done at  New York

On  06/12/2024 (DD/MM/YYYY)

Name & capacity  Patrick Vance, Proxyholder

Signature  

For security reasons, the unsigned form in **xlsx** format should be transmitted to [trp.fin@fsm.a.be](mailto:trp.fin@fsm.a.be). You can do this manually OR if you have MS Outlook at your disposal via the "Save & Send" button.

In addition, a signed copy in **PDF** format should also be transmitted.